➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKesson
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Patent: 8,507,505

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,507,505
Title:Dihydropyrazolopyrimidinone derivative
Abstract: The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar.sup.1 is an optionally substituted aryl or heteroaryl group; R.sup.1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R.sup.2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R.sup.3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy. ##STR00001##
Inventor(s): Bamba; Makoto (Ibaraki, JP), Furuyama; Hidetomo (Kanagawa, JP), Sakamoto; Toshihiro (Ibaraki, JP), Sunami; Satoshi (Ibaraki, JP), Takahashi; Keiji (Chiba, JP), Yamamoto; Fuyuki (Ibaraki, JP), Yoshizumi; Takashi (Ibaraki, JP)
Assignee: MSD K.K. (Chiyoda-Ku, Tokyo, JP)
Application Number:13/133,673
Patent Claims:see list of patent claims

Details for Patent 8,507,505

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX Orphan search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   Start Trial MSD K.K. (Chiyoda-Ku, Tokyo, JP) 2028-12-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Colorcon
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.